Recent advances of highly selective CDK4/6 inhibitors in breast cancer.

Xu H, Yu S, Liu Q, Yuan X, Mani S, Pestell RG, Wu K. Recent advances of highly selective CDK4/6 inhibitors in breast cancer. J Hematol Oncol. 2017 Apr 24; 10(1):97.

View in: PubMed

subject areas

Aminopyridines
Antineoplastic Agents, Immunological
Benzimidazoles
Breast Neoplasms
Cell Cycle
Clinical Trials as Topic
Cyclin-Dependent Kinase 4
Cyclin-Dependent Kinase 6
Drug Screening Assays, Antitumor
Female
Humans
Molecular Targeted Therapy
Neoplasm Proteins
Piperazines
Purines
Pyridines
Therapies, Investigational

authors with profiles

Kongming Wu
Richard Pestell

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement